ArticleTheranostics2020
Theranostic application of
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Emerging miRNA biomarkers in breast cancer: The role of miR-223, miR-326, and miR-429 in tumor profiling.Molecular biology reports · 2026Article
- KY216-tubulin complex captures VASH2 to inhibit NSCLC metastasis.Nature communications · 2025Article
- Radio-chemotherapy and metformin selectively modulate the heterogeneous landscape of glioma with ribosome biogenesis, long non coding RNA and immune-escape markers as major player.International journal of biological sciences · 2025Article
- Article
- Circular RNA circLIFR suppresses papillary thyroid cancer progression by modulating the miR-429/TIMP2 axis.Journal of cancer research and clinical oncology · 2024Article
- Quantitative Changes in Pro-Oncogenic and Tumor-Suppressing MicroRNA in the Regional Lymph Node during Photodynamic Therapy of Experimental Breast Cancer.Bulletin of experimental biology and medicine · 2024Article
- MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway.Cancer biology & therapy · 2023Article
- Influence of Chemotherapy on the Relationship between MicroRNA Levels in the Lymph with Thymus Structure in Experimental Breast Cancer.Bulletin of experimental biology and medicine · 2023Article
- CMA mediates resistance in breast cancer models.Cancer cell international · 2023Article
- VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.Biomolecules & biomedicine · 2023Review
- The mechanism of the Nfe2l2/Hmox1 signaling pathway in ferroptosis regulation in acute compartment syndrome.Journal of biochemical and molecular toxicology · 2023Article
- Specific Antibodies to the Fragments of Meningococcal IgA1 Protease during the Formation of Immunity to Bacterial Infections.Bulletin of experimental biology and medicine · 2022Article
- Effect of Photodynamic Therapy on the microRNA Level in Breast Cancer Tissues of Female Wistar Rats.Bulletin of experimental biology and medicine · 2022Article
- Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer.Life (Basel, Switzerland) · 2022Review
- hsa‑miR‑429 targets CBX8 to promote cell apoptosis in diffuse large B‑cell lymphoma.Molecular medicine reports · 2021Article
- Human microRNA similarity in breast cancer.Bioscience reports · 2021Article
- Berberine inhibits the proliferation, invasion and migration of endometrial stromal cells by downregulating miR‑429.Molecular medicine reports · 2021Article
- Theranostic Advances in Breast Cancer in Nuclear Medicine.International journal of molecular sciences · 2021Review
- Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates.Scientific reports · 2021Article
- EPDR1, Which Is Negatively Regulated by miR-429, Suppresses Epithelial Ovarian Cancer ProgressionFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed/amplified in one third of breast cancers (BCs), and is associated with the poorer prognosis and the higher metastatic potential in BC. Emerging evidences highlight the role of microRNAs (miRNAs) in the regulation of several cellular processes, including BC.
methodsHere we identified, by
resultsWe found that their expression is dysregulated in both HER2+ BC cell lines and human samples. Focusing our study on the only upregulated miRNA,
conclusionsIn HER2+ BC oncogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.